Haoda Fu, PhD
Research Advisor,
Eli Lilly and Company;
Adjunct Professor,
Biostatistics Dept.,
Indiana University,
USA

July 12th,
Thursday
9-10 am EST

If you are interested, please email us at: **MEDecc.US@ boehringer-ingelheim.com** with the subject line "I want to attend Webinar 11 on July 12th, please send me the link"

Title

The Future is Now, but Where We Should Focus

Abstract

New technology enable alternative data types, such as unstructured data, streaming data, and big data. There are challenges and opportunities. Naively applying data science package can result in bias and misleading results which will put a risk to patients. What are the common issues? And where we should focus? This talk will provide our perspective based on recent enterprise initiative on advanced analytics and data science from Eli Lilly and Company.

Professional Biography

Dr. Haoda Fu is a research advisor and the enterprise lead for Machine Learning, Artificial Intelligence, and Digital Connected Care from Eli Lilly and Company. He is also an adjunct professor of biostatistics department, Indiana University School of Medicine. Dr. Fu received his Ph.D. in statistics from University of Wisconsin - Madison in 2007 and joined Lilly after that. Since he joined Lilly, he is very active in statistics methodology research. He has more than 70 publications in the areas, such as Bayesian adaptive design, survival analysis, personalized medicine, indirect and mixed treatment comparison, joint modeling, Bayesian decision making, and drug safety evaluation for rare events. In recent years, his research area focuses on machine learning and artificial intelligence.

Sponsored by

- American Statistical Association (Boston, Connecticut, Florida, New Jersey, Princeton/Trenton, and Washington chapters)
- Boehringer Ingelheim Pharmaceuticals, Inc. (Biostatistics and Data Sciences Department)

Boehringer Ingelheim

ASA | AMERICAN STATISTICAL ASSOCIATION
Promoting the Practice and Profession of Statistics®